Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis
Sponsor study identifier
observational
N/A
0 countries
N/A
Study Start
August 2000
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
July 2004
Date type not reportedThis date has not been verified as actual or estimated.
Responsiveness of recombinant human erythropoietin (rHuEPO) is known to be related with body fatness in hemodialysis (HD) patients. Adiponectin (ADPN) is inversely associated with body fat mass, and in healthy subjects, low ADPN is a predictor of mortality. Recently, higher rHuEPO dose itself is demonstrated to be associated with poor prognosis. So, in this study, we prospectively examined the relationship between rHuEPO dose, serum ADPN, and mortality in patients beginning HD.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2004
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2000
Date type not reportedThis date has not been verified as actual or estimated.
July 2004
Date type not reportedThis date has not been verified as actual or estimated.
April 5, 2007
Actual (reported)April 6, 2007
Actual (reported)Contact the study team to confirm eligibility.
Naro Ohashi, MD,PhD
First Department of Medicine, Hamamatsu University School of Medicine
First Submitted
April 5, 2007
First Posted
April 6, 2007
Study Start
August 2000
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
July 2004
Date type not reportedThe Effect of Food Intake During Hemodialysis on Blood Pressure
This date has not been verified as actual or estimated.
Last Updated
April 6, 2007
Record last verified: 2007-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: